Background. Nuclear factor-kB (NF-kB) regulates many genes involved in vascular physiopathology. Angiotensin II (Ang II) participates in the pathogenesis of several cardiovascular diseases. In a model of atherosclerosis, we have noted NF-kB activation in the neointimia lesion that was decreased by angiotensin-converting enzyme (ACE) inhibitors. However, the potential direct effect of Ang II in the vascular activation of NF-kB has not been completely elucidated. Methods. We ®rst investigated whether Ang II elicited in vivo activation of NF-kB in large vessels of normal rats by systemic infusion of Ang II (50 ngukgumin, s.c.) into rats for 72 h. In order to investigate the receptor involved in this process, we also studied the direct effect of Ang II on cultured vascular smooth muscle cells (VSMCs) from wild-type and AT 1 knockout mice. Results. Ang II-infused rats showed activated NF-kB in the endothelial and vascular smooth muscle cells of the aorta (southwestern histochemistry). In cultured VSMCs from wild-type mice, Ang II increased NF-kB activity that was partially inhibited by AT 1 (losartan) and AT 2 (PD123319) antagonists. In VSMC from AT 1 knockout mice, Ang II also activated NF-kB. Conclusions. These data show that Ang II via AT 1 and AT 2 activates NF-kB in vascular cells both in vivo and in vitro, and suggest a potential involvement of the AT 2 receptor in the pathogenesis of vascular diseases, including hypertension and atherosclerosis.
Introduction
The renin±angiotensin system (RAS) plays an important role in several cardiovascular diseases associated with vascular smooth muscle cell (VSMC) growth and in¯ammation, including hypertension, atherosclerosis, myocardial infarction, cardiac hypertrophy and congestive heart failure w1x. Angiotensin II (Ang II), the main effector peptide of this system, has been implicated not only as a regulator of blood pressure and water±electrolyte balance w2x, but also as a cellular growth factor w3x. Ang II regulates vascular hypertrophyuhyperplasia w4x, vascular cell migration w5x, extracellular matrix production w6x and expression of proin¯ammatory genes w7x.
Ang II acts through its binding to speci®c cellular receptors, AT 1 and AT 2 being the best characterized w8,9x. AT 1 receptors mediate many important cardiovascular responses, such as vasoconstriction, vascular and cardiac remodelling and cell survivaludeath w8,9x. AT 2 receptors are involved in apoptosis, inhibition of cell growth, in¯ammatory cell recruitment and activation of the kininunitric oxide (NO)ucGMP system resulting in cardioprotection, vasodilation and pressure natriuresis w8±10x. Ang II activates various nuclear transcription factors, including the STAT (signal transducer and activator transcription factor), AP-1 (activator protein-1) and CREB (cyclic AMP response element-binding protein) w11±13x. We have demonstrated recently that Ang II activates nuclear factor-kB (NF-kB) in VSMCs and mesangial cells w14,15x. NF-kB is of special interest because it plays a pivotal role in the control of several genes, such as cytokines, chemokines, adhesion molecules, NO synthase, cyclooxygenase-2 and angiotensinogen, involved in the pathogenesis of vascular injury w16,17x. In fact, elevated tissue NF-kB activity has been described in human and experimental models of atherosclerosis, correlated with increased macrophage in®ltration and monocyte chemoattractant protein-1 (MCP-1) expression, that diminished by angiotensin-converting enzyme (ACE) inhibition w14,18x. Inhibition of NF-kB, by the antioxidant pyrrolidine dithiocarbamate, reduces Ang II-induced organ damage in the heart and kidney by preventing in¯ammatory mediators w19x.
Using a pharmacological approach, we recently have demonstrated that in cultured rat VSMCs Ang II activates NF-kB via AT 1 and AT 2 receptors w20x. In addition, systemic infusion of Ang II increased NF-kB and in¯ammation in the kidney w21x. In the present study, we examined whether Ang II directly regulates NF-kB in large vessels that could be relevant for the pathogenesis of hypertension and atherosclerosis. Finally, in AT 1 knockout mice, we evaluated whether Ang II activates NF-kB in VSMCs lacking AT 1 receptors.
Materials and methods

Experimental design
The in vivo effect of Ang II was evaluated by systemic infusion of Ang II (dissolved in saline) into female Wistar rats (s.c. by osmotic minipumps, Alza Corp., CA), at a dose of 50 ngukgumin during 72 h. Then, tissue samples were removed immediately and processed further for histological studies. Control groups of animals of the same age were also studied. Systolic arterial blood pressure was measured in conscious, restrained rats by a tail-cuff sphygmomanometer (NARCO Biosystems, CO). The blood pressure value for each rat was calculated as the average of three separate measurements at each session.
Cell culture
Thoracic aortic VSMCs were isolated from two different strains, AT 1 knockout mice and their wild littermates. The AT 1 knockout mice were generated by a homologous recombination method as previously described w22x, and kindly provided by Dr Sugaya (Tanabe C.C, Osaka, Japan). VSMC cell culture was done as previously described w14x. Brie¯y, fat, connective and adventitial tissues were removed by blunt dissection from the thoracic aorta. Vessels were opened longitudinally and incubated for 30 min with 4 mguml collagenase (type II, 290 Uumg). Cells were counted and seeded at a concentration of 10 4 cellsucm 2 in Dulbecco's modi®ed Eagle's medium (DMEM; Roswell Park Memorial Institute, Buffalo, NY) with 100 Uuml penicillin, 100 mguml streptomycin and 2 mmolul glutamine. Cells were harvested for passaging at 2-week intervals and used between the 2nd and 7th passage. Cells were characterized by phase contrast microscopy and immuno¯uorescence staining. VSMCs were positive for smooth muscle a-actin and negative for von Willebrand factor (excluding endothelial cells). Con¯uent cells were serum-starved for 48 h and used for experiments.
Analysis of transcription factors activity
Nuclear and cytosolic extracts were obtained as previously described w14,15x. Brie¯y, cells were resuspended in extraction buffer w10 mmolul HEPES pH 7.8, 15 mmolul KCl, 2 mmolul MgCl 2 , 0.1 mmolul EDTA, 1 mmolul dithiothreitol (DTT), 1 mmolul phenylmethylsulfonyl¯uoride (PMSF)x and homogenized. Nuclei and cytosolic fractions were separated by centrifugation, and the nuclei were resuspended in extraction buffer to a ®nal concentration of 0.39 molul KCl and centrifuged at 100 000 g for 30 min. Supernatants were dialysed overnight against a binding buffer containing 20 mmolul HEPES-NaOH (pH 7.6), 20% (vuv) glycerol, 0.1 mmolul NaCl, 5 mmolul MgCl 2 , 0.1 mmolul EDTA, 1 mmolul DTT and 0.5 mmolul PMSF. Protein concentration was quanti®ed by the BCA method. NF-kB DNA binding activity was determined in (5±10 mg) nuclear extracts from treated cells by binding with labelled NF-kB consensus (59-AGT-TGAGGGGACTTTCCCAGGC-39) and gel retardation electrophoresis. Negative controls without cellular extracts, and competition assays with a 100-fold excess of unlabelled NF-kB, mutant NF-kB and AP-1 oligonucleotides, were performed to establish the speci®city of the reaction. When competition assays were done, the unlabelled probe was added to this buffer 10 min prior to the addition of the labelled probe. HeLa cell nuclear extracts were used as a positive control (not shown).
Southwestern histochemistry
Tissue sections were dehydrated, rehydrated, ®xed with 0.5% paraformaldehyde and treated with 5 mmolul levamisole for 30 min. Then, sections were digested with 0.5% pepsin in 1 M HCl for 30 min at 378C, washed twice with HEPES±BSA buffer (10 mmoluL HEPES, 40 mmolul NaCl, 10 mmolul MgCl 2 , 1 mmolul DTT, 1 mmolul EDTA, 0.25% bovine serum albumin), and treated with 0.1 mguml DNase I for 20 min. After that, samples were incubated overnight at 378C with the digoxigenin (DIG)-labelled NF-kB oligonucleotide at a ®nal concentration of 100 pmoluml in HEPES±BSA with 0.5 mguml poly(dI±dC). After washing, samples were incubated with an anti-digoxigenin antibody conjugated alkaline phosphatase (Boehringer) for 1 h at 378C and were revealed with 0.4% NBT and 0.32% X-phosphate. The reaction was stopped with 10 mmolul Tris pH 8, 1 mmolul EDTA. Preparations were mounted with glycerol. Synthetic consensus sense (NF-kB: 59-AGTTGAGGGGACTTTCC-CAGGC-39) and mutant sense (NF-kB: 59-AGTTGAGG-CTCCTTTCCCAGGC-39) probes (Genosys Biotechnology, London) were used. Double-stranded DNA probes were labelled with digoxigenin (DIG oligonucleotide 39 end labelling, Boehringer). Preparations without probe were used as negative controls, and mutant probes were used to test the speci®city of the technique.
Statistical analysis
Results are expressed as the mean"SEM. Signi®cance was established using the t-test and analysis of variance when appropriate. Differences were considered signi®cant if P-0.05.
Results
Angiotensin II activates NF-kB in vessels in vivo Systemic infusion of Ang II (50 ngukgumin, s.c. by osmotic minipumps) caused a slight increase in systolic blood pressure after 72 h (121"9 vs 100"2 mmHg in controls, ns10, P-0.05), but within the normotensive range. We investigated whether Ang II in vivo activates NF-kB in the aorta using a digoxigenin-labelled NFkB oligonucleotide that binds to nuclear active NF-kB complexes w23x. Control rats showed no nuclear staining for NF-kB ( Figure 1A ). In Ang II-infused rats, there was an increase in positive nuclear staining, with activated NF-kB complexes located in VSMCs ( Figure 1B ) and endothelial cells ( Figure 1C) . The semiquantitative score of NF-kB staining of the different groups is shown in Figure 1D . Competition of binding by an excess of 100-fold unlabelled NF-kB oligonucleotide, incubation with a mutant DIG-labelled NF-kB (100 pM) or the absence of DIG-labelled NF-kB did not show any nuclear signal (not shown), demonstrating the speci®city of the binding. These controls were done in each experiment. Previous studies have demonstrated that Ang II regulates NF-kB DNA binding activity in cultured VSMCs and endothelial cells w14,20,24x. All these data strongly suggest a direct Ang II effect on the regulation of NF-kB activity in large vessels.
Angiotensin II activates NF-kB in AT 1 knockout VSMCs
We have demonstrated previously that in cultured VSMCs Ang II activates NF-kB via AT 1 and AT 2 receptors w14,20x. To investigate this point further, two different strategies were employed: a genetic approach using VSMCs from AT 1 knockout mice and a pharmacological approach using selective non-peptidic antagonists for AT 1 and AT 2 .
Growth-arrested AT 1 knockout VSMCs were treated with Ang II (10 À7 and 10 À9 molul) for 30, 60 and 120 min. After incubation, nuclear extracts were obtained and NF-kB activity was determined by an assay of nuclear proteins binding to an oligoconsensus labelled with c-32 P. In AT 1 knockout VSMCs, Ang II increased NF-kB DNA binding activity as early as at 15 min, peaked at 60 min and declined by 2 h. The maximal response was observed after 1 h with 10 À7 molul Ang II (3.7-fold over control, ns4, P-0.05), with an intensity similar to tumour necrosis factor-a and interleukin-1b (Figure 2 ). The reaction was proved to be speci®c since the band disappeared when an excess of cold NF-kB (100-fold) was added (Figure 2A) . However, no effect was observed in competition with mutant NF-kB or an unrelated oligonucleotide (AP-1) (not shown). In wild-type mice VSMCs, Ang II also increased NF-kB DNA binding activity, with kinetics similar to AT 1 knockout VSMCs, being maximal after 60 min with 10 À7 molul Ang II (4.8-fold over control, ns2, P-0.05) (Figure 3) .
To investigate further the receptor involved in the Ang II±NF-kB pathway, wild-type VSMCs were pre-incubated with the speci®c receptor antagonists, losartan for AT 1 and PD123319 for AT 2 (10 À5 molul), and then stimulated with 10 À7 molul Ang II for an additional 60 min. Both antagonists partially blocked the Ang II-induced NF-kB DNA binding (Figure 3) . These results were similar to that observed in rat VSMCs w20x. Taken together, these results suggest that Ang II-induced NF-kB DNA binding activity was mediated by both AT 1 and AT 2 receptors.
Discussion
Elevated tissue NF-kB has been observed in certain pathological conditions, associated with RAS activation, including atherosclerotic lesions in humans w14±19x. The blockade of NF-kB by several inhibitors, IkB overexpression and NF-kB decoy oligonucleotides reduces cardiac and vascular damage w19,26,27x. Different therapeutic strategies, such as ACE inhibitors, statins, gucocorticoids and antioxidants, decreased the tissue activity of NF-kB in models of atherosclerosis and vascular injury w14±19,28,29x. In the present study, we have found that Ang II infusion into normal rats activates NF-kB in the aorta, located in VSMCs and endothelial cells. In vitro, Ang II activates NF-kB in VSMCs, endothelial and mononuclear cells w14,20, 24,30x and the expression of NF-kB-regulated genes w7, 10,14,15,20,24,31,32x . The present data reinforce the idea that Ang II could participate in vascular damage via the NF-kB pathway.
A common feature of all stages of atherosclerosis is in¯ammation of the vessel wall. NF-kB regulates many genes encoding cytokines, chemokines and adhesion molecules, that play key roles in the in¯ammatory process w17x. Several studies have pointed out a role for Ang II in in¯ammation. In cultured cells, Ang II increased proin¯ammatory genes w7,10,14,15,31,32 and induced monocyte adhesion w33x. In vivo, infusion of Ang II in rats causes hypertension characterized by marked monocyte in®ltration and vascular cell adhesion molecule (VCAM) and MCP-1 expression in the aorta w31,34x. In hypertensive rats, the presence of monocytesumacrophages in the vessel wall is reduced by ACE inhibitors w35x. In an experimental model of atherosclerosis, ACE inhibition diminished NF-kB activity and chemokine expression in the lesion w14,29x. All these data suggest that Ang II could contribute to in¯ammatory events in atherosclerosis and hypertension via the NF-kB pathway through the regulation of vascular in¯ammatory genes.
Pharmacological and molecular studies are contributing to understanding AT 1 uAT 2 functions. Speci®c receptor antagonists have demonstrated that AT 1 is involved in cell proliferation, and in the production of cytokines and extracellular matrix proteins in cultured cells w3,7,8,9x, as well as in the pathogenesis of Ang IIinduced hypertension and cardiac hypertrophy w36,37x. The AT 2 receptor is associated with inhibition of cell proliferation w9x, and neointimal formation after vascular injury, as shown by treatment with the AT 2 ligand CGP42112 and overexpression of AT 2 w38,39x. Moreover, the in vivo trophic effects of VSMCs are AT 2 mediated w40,41x. Other processes regulated by AT 2 include blood pressure control and renal natriuresis w9x. On the other hand, some Ang II responses could be mediated by both AT 1 and AT 2 , including NO release, collagen synthesis and a 2 -adrenoreceptor activity w42±44x, and, as we have observed, NF-kB activation. In this work, we have demonstrated that in AT 1 knockout mice VSMCs, Ang II caused a rapid increase in NF-kB DNA binding activity, clearly demonstrating that Ang II activates NF-kB via AT 2 . In addition, in wild-type VSMCs, Ang II activates NF-kB via both AT 1 and AT 2 , as shown by speci®c receptor antagonists. These data con®rm our previous studies in rat VSMCs where we showed that AT 1 and AT 2 mediate Ang II-induced NF-kB DNA binding and transcription of an NF-kB reporter gene w20x.
In cultured cells, Ang II via the AT 1 ±NF-kB pathway up-regulates some genes, such as interleukin-6, VCAM-1 and MCP-1 w7,20,24,32x. In vascular smooth muscle cells, Ang II increased the VCAM-1 gene and transactivated an NF-kB-driven VCAM-1 promoter through AT 1 w20x. These data suggest that the proin¯ammatory actions of Ang II could be mediated by the induction of in¯ammatory genes via the AT 1 ±NF-kB pathway. Another important NF-kBcontrolled gene induced by Ang II is angiotensinogen that is induced via AT 1 ±NF-kB in hepatocytes w45x, suggesting a possible autocrine reinforcing loop involved in local Ang II production that could contribute to perpetuation of tissue damage. In contrast, we have observed that Ang II activates NF-kB in AT 1 knockout mice VSMCs, and we previously demonstrated that an AT 2 agonist increased NF-kB DNA binding and mediated gene transcription w20x, showing that Ang II could act via the AT 2 ±NF-kB pathway. In the kidney, Ang II causes in¯ammatory cell in®ltra-tion that was diminished by AT 2 antagonists w21x. We recently have found that in Ang II-infused animals, AT 1 and AT 2 antagonists diminished renal NF-kB activity. Both antagonists decreased NF-kB-positive cells in the glomeruli, the AT 1 blocker markedly in tubules and the AT 2 antagonist in interstitial in®ltrat-ing cells w21x. In addition, AT 2 mediates the induction of the chemokine RANTES in glomerular endothelial cells, showing a possible gene target for the AT 2 ±NF-kB pathway w10x. Other important candidates regulated by the AT 2 ±NF-kB pathway are inducible NO synthase and cycloxygenase-2 w46,47x, which are involved in NOucGMP and prostanglandin and thromboxane production, respectively, in in¯ammatory diseases. Recently, in VSMCs we have unravelled some of the intracellular signals elicited by AT 1 and AT 2 . The potential mechanism of AT 1 ±NF-kB gene regulation could be dependent on redox-sensitive signals and activation of protein tyrosine kinases and mitogen-activated protein, as occurs with proin¯am-matory cytokines, while the AT 2 ±NF-kB pathway seems to be mediated by ceramide production w20x. These data suggest that Ang II, acting mainly via AT 1 , and in particular conditions through AT 2 , could regulate several NF-kB-related genes involved in the pathogenesis of cardiovascular diseases (Figure 4) .
Several studies have shown that AT 2 plays a key role in cardiovascular diseases w9x. AT 2 is re-expressed in organs undergoing remodelling and in fetal tissues w9x. Moreover, AT 1 antagonists increased plasma Ang II levels that could bind to AT 2 ; therefore, understanding the clinical importance of AT 2 stimulation or inhibition is a very interesting unresolved point. Another open question is the relationship between Ang IIu NF-kB and cell growthuapoptosis. Activation of NF-kB and apoptosis of VSMCs have been found in atherosclerosic lesions w48x, and AT 2 is involved in both processes w9,20x. Stimulation of AT 2 inhibits growth of VSMCs, but AT 2 blockade inhibits medial smooth muscle hypertrophy and ®brosis in hypertensive rats w40,41,49x, and deletion of AT 2 suppressed cardiac hypertrophy w50x. Further studies are necessary to elucidate the in vivo relationship between NF-kB and the regulation of cell growthuapoptosis and the role of AT 1 uAT 2 .
Taken together, our data show that Ang II via AT 1 and AT 2 activates NF-kB in vascular cells both in vivo and in vitro, and suggest a potential implication of the AT 2 receptor in the pathogenesis of vascular diseases, including hypertension and atherosclerosis. Ang II, via AT 1 and AT 2 , activates NF-kB and related genes involved in tissue damage. Some proin¯ammatory genes could be induced via AT 1 ±NF-kB, others via AT 2 ±NF-kB, or via both receptors, depending on the cell tissue and pathological conditions.
